Open access · CC-BY
via OpenAlex
Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone
Aging and Disease · 2020 · ▲ 43 citations
Abstract
This population-based retrospective cohort study investigated dementia risk associated with acarbose in patients with type 2 diabetes mellitus by using Taiwan's National Health Insurance database. A cohort of 15,524 matched pairs of ever and never users of acarbose based on propensity score matching was enrolled from new-onset type 2 diabetes patients from 1999 to 2006. Patients who were alive on January 1, 2007, were followed up for dementia until December 31, 2011. Adjusted hazard ratios were estimated using Cox proportional hazards models. The results revealed that the incident case numbers (incidence rates) of dementia were 264 (407.19 per 100,000 person-years) for never users and 231 (337.94 per 100,000 person-years) for ever users. The hazard ratio for ever users versus never users was 0.841 (95% confidence interval, 0.704-1.005) and 0.918 (0.845-0.998) for every 1-year increment of cumulative duration of acarbose therapy. Subgroup analyses showed that the reduced risk associated with acarbose was only observed in women (adjusted hazard ratio, 0.783; 95% confidence interval, 0.618-0.992) and in non-users of metformin (adjusted hazard ratio, 0.635; 95% confidence interval, 0.481-0.837). A model comparing different combinations of acarbose, metformin, and pioglitazone suggested that users of all three drugs had the lowest risk of dementia (hazard ratio, 0.406; 95% confidence interval, 0.178-0.925). In conclusion, reduced risk of dementia associated with acarbose is observed in the female sex and in non-users of metformin. Moreover, users of all three drugs (acarbose, metformin, and pioglitazone) have the lowest risk of dementia.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.14336/ad.2019.0621
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Tseng, C. (2020). Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone. <em>Aging and Disease</em>. https://doi.org/10.14336/ad.2019.0621
Vancouver
Tseng C. Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone. Aging and Disease. 2020. doi:10.14336/ad.2019.0621.
BibTeX
@article{chinhsiao2020Dement,
title = {Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone},
author = {Chin‐Hsiao Tseng},
journal = {Aging and Disease},
year = {2020},
doi = {10.14336/ad.2019.0621},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Brain 2023
Open access · OA
Metformin in elderly type 2 diabetes mellitus: dose-dependent dementia risk reduction
Otolaryngology 2023
Open access · OA
Metformin Reduces the Risk of Hearing Loss: A Retrospective Cohort Study
Communications Medicine 2025
Open access · CC-BY
Proteomics-based aging clocks in midlife or late-life and their associated risk of dementia
Research Square 2025
Preprint · CC-BY
Proteomics-based aging clocks in midlife and late-life and risk of dementia
Alzheimer s & Dementia 2023
Open access · CC-BY
Dementia risk in patients with type 2 diabetes: Comparing metformin with no pharmacological treatment
Journal of Ophthalmology 2019
Open access · CC-BY